Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkae456 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Inés Suárez-García und 12 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Group, Department of Internal Medicine, Hospital Universitario Infanta Sofia, FIIB HUIS HUHEN, Madrid, Spain. Hauptthemen laut MEDLINE: Piperazines, Heterocyclic Compounds, 3-Ring, HIV Infections, Lamivudine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIBER-Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Objectives
To evaluate the long-term effectiveness, persistence and tolerability of dolutegravir (DTG)/lamivudine (3TC), compared with the most frequently prescribed first-line treatment regimens, among antiretroviral-naive people with HIV from CoRIS, a multicentre cohort in Spain, in 2018–23.
Methods
We used multivariable regression models to compare viral suppression (VS) (HIV RNA viral load <50 copies/mL), change in CD4 cell counts, persistence and treatment discontinuations due to adverse events (AEs), at 96 (±24) weeks after treatment initiation.
Results
Of 2359 participants, DTG/3TC was prescribed in 472 (20.0%), bictegravir/tenofovir alafenamide (TAF)/emtricitabine (FTC) in 1134 (48.1%), DTG + tenofovir disoproxil fumarate/FTC in 300 (12.7%), DTG/abacavir/3TC in 273 (11.6%) and darunavir/cobicistat/TAF/FTC in 180 (7.6%). At 96 weeks from treatment initiation, 94.0% of participants initiating with DTG/3TC achieved VS, and the mean increase in CD4 cell counts was 295.5 cells/μL (95% CI: 269.9–321.1). During the first 96 weeks after DTG/3TC initiation, 9.8% and 1.3% discontinued their initial regimen, overall and due to AEs, respectively. In multivariable analyses, we did not find significant differences in VS or increase in CD4 cell counts among participants initiating with DTG/3TC compared with other regimens. Initiating ART with a regimen other than DTG/3TC was associated with a higher risk of treatment discontinuation, overall and due to AEs.
Conclusions
Among treatment-naive people with HIV from this large multicentre cohort, DTG/3TC had similar effectiveness and better persistence and tolerability than those of the most frequently prescribed first-line regimens at 96 weeks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Group, Department of Internal Medicine, Hospital Universitario Infanta Sofia, FIIB HUIS HUHEN, Madrid, Spain.
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Carlos III Health Institute, Madrid, Spain.
- Clinical Department, Facultad de Medicina, Salud y Deporte, Universidad Europea de Madrid, Madrid, Spain.
- Independent Researcher, Madrid, Spain.
- National Centre for Epidemiology, Carlos III Health Institute, Madrid, Spain.
- HIV Unit, Department of Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain.
ORCID-Profile: Inés Suárez-García, Mar Masiá, Lucio J García-Fraile, Roberto Muga, Santiago Moreno
Förderung
- CIBER-Consorcio Centro de Investigación Biomédica en Red
- Instituto de Salud Carlos III
- Ministerio de Ciencia e Innovación
- Unión Europea-NextGenerationEU
- ViiV Healthcare
- CIBER—Consorcio Centro de Investigación Biomédica en Red
- Unión Europea—NextGenerationEU
Zitieren
APA
Suárez-García, I., Alejos, B., Moreno, C., Martín Torres, J., Masiá, M., García-Fraile, L. J., Riera, M., Dalmau, D., Rodríguez-Rosado, R., Muga, R., Moreno, S., Jarrín, I., & CoRIS cohort (2025). Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae456
Vancouver
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, et al. Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae456
BibTeX
@article{SurezGarca2025,
author = {Suárez-García, Inés and Alejos, Belén and Moreno, Cristina and Martín Torres, Juan and Masiá, Mar and García-Fraile, Lucio J and Riera, Melchor and Dalmau, David and Rodríguez-Rosado, Rafael and Muga, Roberto and Moreno, Santiago and Jarrín, Inma and CoRIS cohort, CoRIS cohort},
title = {Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkae456}
}
EUVIMED